Cariprazine (RGH-188): a new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?

Laura Orsolini, Felice Iasevoli, Emiliano Prinzivalli, Alessandro Valchera, Michele Fornaro, Roberta Vecchiotti, Roberto Latiatini, Alessandro Carano, Maurizio Pompili, Giampaolo Perna, Federica Vellante, Ilaria Mataraataraatarazzo, Giovanni Martiartinotti, Andrea de Bartartolomeis, Massimo di Giannantonio, Domenico de Berardis*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)17-25
Number of pages9
JournalMinerva Psichiatrica e Psicologica
Volume58
Issue number1
DOIs
Publication statusPublished - Mar 2017

Keywords

  • Cariprazine
  • Dopamine
  • Schizophrenia
  • Bipolar disorder
  • Depressive disorder, major
  • Antipsychotic agents
  • RECEPTOR PARTIAL AGONIST
  • DOPAMINE D-3 RECEPTOR
  • PHASE-II TRIAL
  • ACUTE MANIA
  • CLINICAL-EFFICACY
  • DOUBLE-BLIND
  • ACUTE EXACERBATION
  • TOLERABILITY
  • SAFETY
  • ANTIPSYCHOTICS

Cite this